WallStreetZenWallStreetZen

NASDAQ: ZVRA
Zevra Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ZVRA

Based on 7 analysts offering 12 month price targets for Zevra Therapeutics Inc

Min Forecast
$25.00+91.42%
Avg Forecast
$29.29+124.24%
Max Forecast
$35.00+167.99%

Should I buy or sell ZVRA stock?

Based on 7 analysts offering ratings for Zevra Therapeutics Inc.

Strong Buy
Strong Buy
5 analysts 71.43%
Buy
2 analysts 28.57%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their ZVRA stock forecasts and price targets.

ZVRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-23
lockedlocked$00.00+00.00%2026-06-11
lockedlocked$00.00+00.00%2026-06-10
lockedlocked$00.00+00.00%2026-06-10
lockedlocked$00.00+00.00%2026-06-09Find Out Why
Citizens
Top 2%
99
BuyMaintains$25.00+91.42%2026-06-09
Cantor Fitzgerald
Top 3%
98
Strong BuyMaintains$34.00+160.34%2026-06-08Find out why

1 of 1

Forecast return on equity

Is ZVRA forecast to generate an efficient return?

Company
81.82%
Industry
91.92%
Market
170.5%
ZVRA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ZVRA forecast to generate an efficient return on assets?

Company
60.44%
Industry
27.48%
ZVRA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ZVRA earnings per share forecast

What is ZVRA's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$1.05-48.94%
Avg 2 year Forecast
$0.90-56.18%
Avg 3 year Forecast
$1.97-4.11%
ZVRA's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ZVRA revenue forecast

What is ZVRA's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$149.8M+22.46%
Avg 2 year Forecast
$183.9M+50.39%
Avg 3 year Forecast
$265.1M+116.77%
ZVRA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ZVRA earnings growth forecast

How is ZVRA forecast to perform vs Biotechnology companies and vs the US market?

Company
-5.2%
Industry
15.71%
Market
34.28%
ZVRA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ZVRA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ZVRA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ZVRA revenue growth forecast

How is ZVRA forecast to perform vs Biotechnology companies and vs the US market?

Company
29.42%
Industry
35.2%
Market
14.11%
ZVRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ZVRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ZVRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ZVRA$13.06$29.29+124.24%Strong Buy
KZIA$13.47$25.67+90.55%Strong Buy
RIGL$41.17$69.00+67.60%Strong Buy
OMER$10.50$34.50+228.57%Strong Buy
CLYM$13.24$21.08+59.24%Strong Buy
View Top Biotech Stocks

Zevra Therapeutics Stock Forecast FAQ

Is Zevra Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: ZVRA) stock is to Strong Buy ZVRA stock.

Out of 7 analysts, 5 (71.43%) are recommending ZVRA as a Strong Buy, 2 (28.57%) are recommending ZVRA as a Buy, 0 (0%) are recommending ZVRA as a Hold, 0 (0%) are recommending ZVRA as a Sell, and 0 (0%) are recommending ZVRA as a Strong Sell.

If you're new to stock investing, here's how to buy Zevra Therapeutics stock.

What is ZVRA's earnings growth forecast for 2026-2028?

(NASDAQ: ZVRA) Zevra Therapeutics's forecast annual earnings growth rate of -5.2% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.28%.

Zevra Therapeutics's earnings in 2026 is $124,218,000.On average, 11 Wall Street analysts forecast ZVRA's earnings for 2026 to be $61,875,758, with the lowest ZVRA earnings forecast at $46,174,792, and the highest ZVRA earnings forecast at $81,312,798. On average, 11 Wall Street analysts forecast ZVRA's earnings for 2027 to be $53,108,991, with the lowest ZVRA earnings forecast at $16,221,179, and the highest ZVRA earnings forecast at $93,726,966.

In 2028, ZVRA is forecast to generate $116,202,521 in earnings, with the lowest earnings forecast at $47,504,882 and the highest earnings forecast at $193,040,307.

What is ZVRA's revenue growth forecast for 2026-2028?

(NASDAQ: ZVRA) Zevra Therapeutics's forecast annual revenue growth rate of 29.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.2%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.11%.

Zevra Therapeutics's revenue in 2026 is $122,289,000.On average, 11 Wall Street analysts forecast ZVRA's revenue for 2026 to be $8,853,074,980, with the lowest ZVRA revenue forecast at $7,843,980,496, and the highest ZVRA revenue forecast at $10,179,617,465. On average, 11 Wall Street analysts forecast ZVRA's revenue for 2027 to be $10,871,855,098, with the lowest ZVRA revenue forecast at $8,967,758,243, and the highest ZVRA revenue forecast at $14,164,565,277.

In 2028, ZVRA is forecast to generate $15,670,817,618 in revenue, with the lowest revenue forecast at $12,623,435,037 and the highest revenue forecast at $21,811,692,543.

What is ZVRA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ZVRA) forecast ROA is 60.44%, which is higher than the forecast US Biotechnology industry average of 27.48%.

What is ZVRA's Price Target?

According to 7 Wall Street analysts that have issued a 1 year ZVRA price target, the average ZVRA price target is $29.29, with the highest ZVRA stock price forecast at $35.00 and the lowest ZVRA stock price forecast at $25.00.

On average, Wall Street analysts predict that Zevra Therapeutics's share price could reach $29.29 by Jun 23, 2027. The average Zevra Therapeutics stock price prediction forecasts a potential upside of 124.24% from the current ZVRA share price of $13.06.

What is ZVRA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ZVRA) Zevra Therapeutics's current Earnings Per Share (EPS) is $2.05. On average, analysts forecast that ZVRA's EPS will be $1.05 for 2026, with the lowest EPS forecast at $0.78, and the highest EPS forecast at $1.38. On average, analysts forecast that ZVRA's EPS will be $0.90 for 2027, with the lowest EPS forecast at $0.27, and the highest EPS forecast at $1.59. In 2028, ZVRA's EPS is forecast to hit $1.97 (min: $0.80, max: $3.27).

What is ZVRA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ZVRA) forecast ROE is 81.82%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.